Our story

Early research starts with two searches. I put them on one page.

I'm Johnny Mobley. I started building systems for other people in 2000, when I was 16, and I've been doing it ever since. Along the way I automated most of my own work, and the tools I built for myself became these companies. Each one runs on rules I wrote down, not on paid AI calls, which is why it can cost so little.

When you start looking into a drug, a gene or a pathway, the first hour goes to the same two places: the registry of clinical trials and the published papers. I built YutaniAI so both searches sit side by side and come back as plain lists: trial number, sponsor and status; paper, journal, date and first author.

The results come straight from ClinicalTrials.gov and PubMed. It is a research aid only. It doesn't interpret the studies, it isn't medical advice, and the written summary of the evidence isn't built yet.

What works today

• Searches registered clinical trials and lists each trial's number, title, sponsor and status
• Searches published papers on PubMed and lists title, journal, date and first author

What it doesn't do yet

Elicit still does things YutaniAI doesn't:

• A written summary of the evidence across papers.
• Reading full-text papers and pulling data out into tables.
• Exporting results to a reference manager.
• Systematic-review screening workflows.

What it costs

Elicit's price is from their pricing page as of October 29, 2026. Prices change, so check theirs before you compare.

— Johnny